The most common side effects of AUSTEDO in people with tardive dyskinesia include inflammation of the nose and throat (nasopharyngitis) and problems sleeping (insomnia). The most common side …

AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …

Aug 20, 2025 · Austedo is used to treat the involuntary movements of Huntington's disease and tardive dyskinesia (TD). Includes Austedo side effects, dosage, uses, interactions, and more

Nov 26, 2025 · Learn about the FDA-approved treatment for tardive dyskinesia, specifically the VMAT2 inhibitors valbenazine (Ingrezza) and deutetrabenazine (Austedo).

Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 inhibitor approved …

2 days ago · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.

Nov 26, 2025 · Key Takeaways Deutetrabenazine and its extended-release formulation show efficacy in reducing involuntary movements and enhancing quality of life in tardive dyskinesia patients. The …

Austedo is a brand of deutetrabenazine. This medication treats involuntary movements caused by tardive dyskinesia or Huntington's disease.

Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.

VMAT2 inhibitors: There are two FDA-approved drugs to treat tardive dyskinesia, Ingrezza (valbenazine) and Austedo (deutetrabenazine). These medications were approved in 2017 and are known as …